Aneusomy 17 in breast cancer: its role in HER-2/neu protein expression and implication for clinical assessment of HER-2/neu status. - Wikidata - wikimedia - TriplyDB

Aneusomy 17 in breast cancer: its role in HER-2/neu protein expression and implication for clinical assessment of HER-2/neu status.

Aneusomy 17 in breast cancer: its role in HER-2/neu protein expression and implication for clinical assessment of HER-2/neu status.

http://www.wikidata.org/entity/Q38457772

about

Defining the sister rat mammary tumor cell lines HH-16 cl.2/1 and HH-16.cl.4 as an in vitro cell model for Erbb2 Polysomy of chromosome 17 in breast cancer tumors showing an overexpression of ERBB2: a study of 175 cases using fluorescence in situ hybridization and immunohistochemistry.HER2 in situ hybridization in breast cancer: clinical implications of polysomy 17 and genetic heterogeneity Clinical validation of an array CGH test for HER2 status in breast cancer reveals that polysomy 17 is a rare event Analysis of EGFR, HER2, and TOP2A gene status and chromosomal polysomy in gastric adenocarcinoma from Chinese patients.Correlation of HER2 overexpression with gene amplification and its relation to chromosome 17 aneuploidy: a 5-year experience with invasive ductal and lobular carcinomas Testing for HER2 in Breast Cancer: A Continuing Evolution.HER2/neu Immunostaining in Invasive Breast Cancer: Analysis of False Positive Factors.The Clinicopathologic and Prognostic Value of Altered Chromosome 17 Centromere Copy Number in HER2 Fish Equivocal Breast Carcinomas Frequencies of HER-2/neu expression and gene amplification in patients with oesophageal squamous cell carcinoma.Development of NIST standard reference material 2373: Genomic DNA standards for HER2 measurements.The role of HER2 in early breast cancer metastasis and the origins of resistance to HER2-targeted therapies.Breast cancer and aneusomy 17: implications for carcinogenesis and therapeutic response.Assessment of HER2 gene status in breast carcinomas with polysomy of chromosome 17.Advantages and disadvantages of technologies for HER2 testing in breast cancer specimens.Potential Biomarkers in Diagnosis of Human Gastric Cancer.MicroRNA-21 Expression in Primary Breast Cancer Tissue Among Egyptian Female Patients and its Correlation with Chromosome 17 Aneusomy.Clinical role of HER2 gene amplification and chromosome 17: a study on 154 IHC-equivocal cases of invasive breast carcinoma patients.Lack of independent prognostic and predictive value of centromere 17 copy number changes in breast cancer patients with known HER2 and TOP2A status.Monosomy of chromosome 17 in breast cancer during interpretation of HER2 gene amplification.Impact of polysomy 17 on HER-2/neu immunohistochemistry in breast carcinomas without HER-2/neu gene amplification.Comparison of two quantitative polymerase chain reaction methods for detecting HER2/neu amplification.Role of polysomy 17 in transitional cell carcinoma of the bladder: immunohistochemical study of HER2/neu expression and fish analysis of c-erbB-2 gene and chromosome 17.Analysis of HER-2/neu amplification in endometrial carcinoma by chromogenic in situ hybridization. Correlation with fluorescence in situ hybridization, HER-2/neu, p53 and Ki-67 protein expression, and outcome.Analysis of HER2 gene amplification and protein expression in esophageal squamous cell carcinoma.Real-time reverse transcription-PCR and fluorescence in-situ hybridization are complementary to understand the mechanisms involved in HER-2/neu overexpression in human breast carcinomas.Reliability of chromogenic in situ hybridization for detecting HER-2 gene status in breast cancer: comparison with fluorescence in situ hybridization and assessment of interobserver reproducibility.Quantitative assessment of HER2 amplification in HER2-positive breast cancer: its association with clinical outcomes.Assessment of HER2 status in invasive breast cancers with increased centromere 17 copy number.Correlation of HER-2/Neu protein expression and HER2 gene amplification with clinical morphological parameters of nonsmall cell lung cancer.Prognostic value of TOP2A gene amplification and chromosome 17 polysomy in early breast cancer.The HER2 gene copies per tumor cell either before or after correction for chromosome-17 correlated significantly with HER2 IHC results in epithelial ovarian cancer in a tissue microarray study.

P2860

Q21134904-46C93C15-5BC1-4F94-AB97-5E4BD58F1DF5 Q24797806-183A8518-8D45-4E1C-893C-A770B1162B90 Q27006811-7181D1DD-C7FC-424A-B76E-39B9BBD2B73D Q28245213-1893B107-BCB8-4621-AE93-7469A099643C Q33390513-8D7740AE-618B-4237-8833-3D42A92BBCBE Q34371749-AA19DF9D-166F-40E0-86DE-1B7D51A8242F Q34424285-A4ACED06-2BF5-448C-976E-11651161CEAB Q35323892-A1BCCD8C-AEAC-4F0C-8A4A-276B4B7D113A Q35687706-5BDDF98B-0D9E-4DE5-B2AE-2297C209DEEB Q36616556-52DEF066-4377-47F6-9416-DA5F96BEFE7E Q37000037-CC79A8DE-41CC-40AD-8FED-6462E491528E Q37326072-8D191DBE-8E27-4FD5-BDAA-E332D99840F8 Q37406389-E5B588AF-0721-4E7F-B183-96E6C39B2920 Q38414983-86332310-9601-42B6-B69B-C452264C0CB5 Q38612634-FBBDB64F-347B-4C4A-A426-F704148D9BC9 Q38757877-241CA75E-5310-4954-8694-7B218AA58F54 Q38854683-65AB89E9-DC6B-4DF8-8149-73955141BC87 Q40135743-28EB7717-44C6-4C0B-929B-42CD2B51A711 Q41133771-0CFB9340-EBCE-4BDC-A761-F10BDA9E7B7B Q41821797-BD1690C8-8091-448B-9489-87FFBC41477E Q41955766-564D45B5-61EA-4E2E-B3F4-D3A65E22F117 Q42718689-967BD3D8-370C-4E87-A761-BF08BC15C697 Q43963074-2714F464-7A50-40F1-A7C2-425847F7A258 Q47231231-68352438-76E5-4333-B198-1CA1BE847BAA Q51056791-5C33F086-6BCE-48D2-B92B-E77AF878C7E6 Q51510677-D98E1A44-7382-4039-8D4F-CE03241577E4 Q52976761-67A9D89A-0C21-43BD-A7E4-5A1714673338 Q53581875-4E8F6E17-FCC6-46D2-845F-7F1196E8317D Q54256014-2B059096-889A-409A-9FF3-7813454C25A8 Q54313117-776B64E7-4860-4019-A5C1-368A13B911EF Q54318735-C16A0213-7051-4D23-9F89-7D66906AB37B Q54635889-5E76F71C-F9A3-470E-87A9-2BB68FC3EFFF

P2860

Aneusomy 17 in breast cancer: its role in HER-2/neu protein expression and implication for clinical assessment of HER-2/neu status.

http://www.wikidata.org/entity/Q38457772

description

2002 nî lūn-bûn

@nan

2002年の論文

@ja

2002年論文

@yue

2002年論文

@zh-hant

2002年論文

@zh-hk

2002年論文

@zh-mo

2002年論文

@zh-tw

2002年论文

@wuu

2002年论文

@zh

2002年论文

@zh-cn

name

Aneusomy 17 in breast cancer: ...... ssessment of HER-2/neu status.

@en

type

label

Aneusomy 17 in breast cancer: ...... ssessment of HER-2/neu status.

@en

prefLabel

Aneusomy 17 in breast cancer: ...... ssessment of HER-2/neu status.

@en

P1433

Q38457772-BF0A8EA2-F4D0-4D1E-B943-DA15901E5271

P1476

Q38457772-D4CF4B42-1B2C-4E1D-8A29-682925B32744

P2093

Q38457772-0A71C377-0ABE-487B-AAF6-93D76B853B93

Q38457772-1B19CCFF-ACF6-4E82-904D-FDDDF896C7E4

Q38457772-1E4F2D8E-F164-4040-9C6B-DFBF8D40D7DC

Q38457772-B7020205-C475-47DA-BD57-16F0F2D00A62

Q38457772-BB170D86-6013-4902-877C-3329B0D83B60

Q38457772-C75E913F-C0F0-40E7-8E77-D7A3F099BA7F

Q38457772-DD855583-EE57-42A5-BDE0-A945F889EEBE

P2860

Q38457772-0146C62E-8C5D-4E8C-84DD-BAB4B9173C72

Q38457772-12F91574-D207-45A3-AC74-BB911E54F778

Q38457772-24FB5F02-35E1-444C-8F08-84C22A817AF1

Q38457772-2A91AA83-106F-4586-8F7E-4750DFD44A7A

Q38457772-5B8ACA2A-C215-4665-83FD-E75AD5065BC0

Q38457772-64B5A01B-B4E8-45DA-B125-91AB126D0F49

Q38457772-6956708D-20D9-4E03-A811-7043C3BDE2FF

Q38457772-706ED4D6-EB99-4274-8C58-A47C901BC0FE

Q38457772-B8666434-F888-4CC4-ADAB-543BE414D735

Q38457772-C231CAAB-E199-4B8A-8D6C-364270C4BEC2

P2888

Q38457772-8D35DE39-A9CF-4739-B990-0B6568E73B7D

P304

Q38457772-A0970C74-8C3E-4431-B789-6665106C77C5

P31

Q38457772-CE90A8CD-43D9-4B6D-8EE1-6861B1111B66

P356

Q38457772-B8FF231F-AB76-4181-B507-A90AC1E69F04

P433

Q38457772-AC984B72-C67C-4DAA-B292-5A92E08F4710

P478

Q38457772-D00F7968-A8E8-4A2F-B47E-9A9BE41A07DA

P50

Q38457772-EFFCA7BA-4637-4777-B0ED-CA222DF89E38

P577

Q38457772-DA98B4CC-5452-4E15-9D1B-15A6677F3B7C

P5875

Q38457772-868E8525-75F6-499B-AE4D-8896CC27A2B0

P6179

Q38457772-41F30710-A406-4F53-B85A-FDBF5BB007EF

P698

Q38457772-F89FACDF-B026-4BDB-ABA8-570361058707

P356

MODPATHOL.3880505

P1433

Modern Pathology

P1476

Aneusomy 17 in breast cancer: ...... ssessment of HER-2/neu status.

@en

P2093

Barbara B Haley

http://www.w3.org/2001/XMLSchema#string

Eugene P Frenkel

http://www.w3.org/2001/XMLSchema#string

M Hossein Saboorian

http://www.w3.org/2001/XMLSchema#string

Momin T Siddiqui

http://www.w3.org/2001/XMLSchema#string

Raheela Ashfaq

http://www.w3.org/2001/XMLSchema#string

Sefik Gokaslan

http://www.w3.org/2001/XMLSchema#string

Sijian Wang

http://www.w3.org/2001/XMLSchema#string

P2860

Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene

Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer

Charcot-Marie-Tooth polyneuropathy: duplication, gene dosage, and genetic heterogeneity.

Laboratory assessment of the status of Her-2/neu protein and oncogene in breast cancer specimens: comparison of immunohistochemistry assay with fluorescence in situ hybridisation assays

ERBB2 amplification in breast cancer analyzed by fluorescence in situ hybridization

HER-2/neu gene amplification compared with HER-2/neu protein overexpression and interobserver reproducibility in invasive breast carcinoma.

HER-2/neu signal transduction in human breast and ovarian cancer.

The ErbB signaling network in embryogenesis and oncogenesis: signal diversification through combinatorial ligand-receptor interactions.

Strategies for the analysis of oncogene overexpression. Studies of the neu oncogene in breast carcinoma.

HER-2/neu testing in breast carcinoma: a combined immunohistochemical and fluorescence in situ hybridization approach.

P2888

modpathol.3880505

P304

137-145

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1038/MODPATHOL.3880505

http://www.w3.org/2001/XMLSchema#string

P433

2

http://www.w3.org/2001/XMLSchema#string

P478

15

http://www.w3.org/2001/XMLSchema#string

P50

P577

2002-02-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

11510001

http://www.w3.org/2001/XMLSchema#string

P6179

1032477205

http://www.w3.org/2001/XMLSchema#string

P698

11850542

http://www.w3.org/2001/XMLSchema#string